Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials
Alzheimer's & Dementia · 2026-04 · 22 (4)
DOI: 10.1002/alz.71366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.04.2026. Verfasst von Runpeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Secondary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Epstein Family Foundation, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Biomarkers identify Alzheimer's disease pathology in cognitively unimpaired adults, but the timing and rate of cognitive decline vary widely. This study aimed to identify subgroups of cognitive decline and baseline predictors of heterogeneity in preclinical progression. METHODS Data were drawn from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease Study, which enrolled amyloid beta‐positive (Aβ+) participants, and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, which enrolled amyloid beta‐negative (Aβ−) individuals. Latent class mixed‐effects models identified cognitive trajectory classes. Associations between class membership and demographic, clinical, and biomarker variables were evaluated. The primary outcome was change in the Preclinical Alzheimer Cognitive Composite. RESULTS Three trajectory classes were identified: stable, slow decliners, and fast decliners. Higher phosphorylated tau at 217 (p‐tau217), smaller hippocampal volume, and elevated tau positron emission tomography were associated with declining classes. About 70% of Aβ+ individuals were stable. DISCUSSION Latent class modeling reveals substantial heterogeneity in preclinical trajectories with important implications for prevention trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
- Department of Psychiatry, University of California, San Francisco, California, USA.
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Michael C Donohue
Förderung
- NIA NIH HHS
- Epstein Family Foundation
- Alzheimer's Association
- GHR Foundation
- Foundation for the National Institutes of Health
- Avid Radiopharmaceuticals
- Eli Lilly and Company
- National Institute on Aging
Zitieren
APA
Li, R., Langford, O., Insel, P. S., Sperling, R. A., Raman, R., Aisen, P. S., & Donohue, M. C. (2026). Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71366
Vancouver
Li R, Langford O, Insel PS, Sperling RA, Raman R, Aisen PS, et al. Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71366
BibTeX
@article{Li2026,
author = {Li, Runpeng and Langford, Oliver and Insel, Philip S and Sperling, Reisa A and Raman, Rema and Aisen, Paul S and Donohue, Michael C},
title = {Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {4},
doi = {10.1002/alz.71366}
}
EUVIMED